luveltamab tazevibulin

Antibody–drug conjugate

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-03), as a strategic decision by the sponsor

Sutro stopped further investment in luvelta across all indications in March 2025 and continues to explore out-licensing; the REFRaME-O1 Phase 2/3 study (NCT05870748) was terminated for the same reason. The trials below are kept as the program's evidence history. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
Phase 2 (1)
Other / comorbidity
NCT06555263 · Sutro Biopharma, Inc.
2024-08-21 – 2025-05-01 · Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT06238687 · Tasly Pharmaceutical Group Co., Ltd
2023-11-08 – 2025-12-30 · Neoplasm Malignant
What this study did
NCT06679582 · Sutro Biopharma, Inc.
2024-12-04 – 2025-01-21 · Acute Myeloid Leukemia (AML)
What this study did
Phase 1 (2)
Other / comorbidity
NCT05200364 · Sutro Biopharma, Inc.
2022-03-22 – 2025-06-01 · Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 5 of them ahead of this one.

This drug's own stage for Ovarian Cancer: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Luveltamab Tazevibulin: this drugDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack)ApprovedSmall moleculeMEK1/2 and RAF (CRAF, BRAF), FAKnot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Mirvetuximab Soravtansine (Elahere)ApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
GSK 5733584Phase 3——not yet gradedNo reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BirinapantPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IDE-161Phase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
IMGN-151
Phase 1(overall)
Antibody–drug conjugateFolate receptor alpha (FRα)
not yet graded(overall)
No reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.